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Abstract
Background: Pre-exercise supplements containing low doses of caffeine improve endurance exercise performance,
but the most efficacious time for consumption before intense endurance exercise remains unclear, as does the
contribution of caffeine metabolism.
Methods: This study assessed the timing of a commercially available supplement containing 200 mg of caffeine,
1600 mg of β-alanine and 1000 mg of quercetin [Beachbody Performance Energize, Beachbody LLC, USA] on
exercise performance, perception of effort and plasma caffeine metabolites. Thirteen cyclists (V̇O2max 64.5 ± 1.4 ml
kg− 1 min− 1 (± SEM)) completed four experimental visits consisting of 30 min of steady-state exercise on a cycle
ergometer at 83 ± 1% V̇O2max followed by a 15-min time trial, with perceived exertion measured regularly. On three
of the visits, participants consumed caffeine either 35 min before steady-state exercise (PRE), at the onset of steady-
state (ONS) or immediately before the time trial (DUR) phases, with a placebo consumed at the other two time
points (i.e. three drinks per visit). The other visit (PLA) consisted of consuming the placebo supplement at all three
time points. The placebo was taste-, colour- and calorie-matched.
Results: Total work performed during the time trial in PRE was 5% greater than PLA (3.53 ± 0.14 vs. 3.36 ± 0.13 kJ
kg− 1 body mass; P = 0.0025), but not ONS (3.44 ± 0.13 kJ kg− 1; P = 0.3619) or DUR (3.39 ± 0.13 kJ kg− 1; P = 0.925),
which were similar to PLA. Perceived exertion was lowest during steady-state exercise in the PRE condition (P <
0.05), which coincided with elevated plasma paraxanthine in PRE only (P < 0.05).
Conclusion: In summary, ingestion of a pre-exercise supplement containing 200 mg caffeine 35 min before exercise
appeared optimal for improved performance in a subsequent fatiguing time trial, possibly by reducing the
perception of effort. Whether this was due to increased circulating paraxanthine requires further investigation.
Trial registration: ClinicalTrials.Gov, NCT02985606; 10/26/2016.
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Key Points
 A commercially available supplement containing
200 mg of caffeine, 1600 mg of β-alanine and
1000 mg of quercetin [Beachbody Performance
Energize, Beachbody LLC, USA] ingested 35 min
before, but not immediately before or during, ex-
ercise reduced perceived exertion during 30-min
cycling at 80% VO2max and improved subsequent
15-min cycling time trial (TT) performance in
trained cyclists by 5%.
 Plasma caffeine concentration was elevated during
the TT with all supplement timing strategies, but
paraxanthine was only elevated during the TT
when the supplement was ingested 35 min before
exercise, the only strategy to observe an ergogenic
effect, suggesting a role for paraxanthine which
requires further investigation. Caffeine and
paraxanthine concentrations did not appear to be
dependent upon CYP1A2 genotype, a possible
mediator of an individual’s response to caffeine
ingestion.
 We suggest supplements containing low doses of
caffeine (e.g. 200 mg) should be ingested around 60
min prior to the onset of expected hard exercise in
order to reduce the perception of effort and
maximize the improvement in performance. This is
an improvement on the current broad
recommendation of ingesting caffeine-containing
supplements 60 min before exercise per se.
Background
In efforts to optimize performance, the use of nutritional
supplements is unsurprisingly widespread amongst elite
athletes, with caffeine and multi-ingredient ‘pre-exercise
drinks’ containing caffeine amongst some of the most
commonly used [1, 2]. The ingestion of low doses of caf-
feine (≤ 3 mg kg body mass (bm)− 1) enhances endurance
performance via its role as an adenosine receptor antag-
onist [3]. Indeed, during endurance exercise, adenosine
blockade has been shown to reduce the perception of ef-
fort [4].
Despite vast amounts of research being undertaken
over previous decades, little is currently known about
the most efficacious time to ingest low doses of caffeine,
particularly when consumed in a drink with other ingre-
dients. Current guidelines typically recommend the in-
gestion of caffeine approximately 60 min prior to
exercise [5]. This practice is reflected in research, with a
recent meta-analysis observing that the vast majority of
trials have been performed with caffeine ingested 60 min
prior to a plethora of exercise scenarios [6]. It is, how-
ever, vital to recognize that the duration of the exercise
bouts varies between studies, markedly changing the
period of time between supplementation and the end of
exercise. This is significant as caffeine, due to its effects
on the central nervous system, is likely to be most ergo-
genic when perceived effort is increased, which will pre-
sumably be at its highest towards the end of exercise,
and it appears to have a narrow window of action [6].
For example, it would appear that ingesting low-dose
caffeine 60 min before the latter stages of a time trial
(TT) would be more effective than earlier (> 80min) or
later (< 40min) [6], but this is yet to be tested under
identical experimental conditions.
The finding that the effects of ingesting caffeine tend
to wane > 80min prior to the end of a TT appears to be
at odds with the fact that plasma caffeine concentrations
remain elevated at a steady state for several hours after
ingestion [7]. This is in line with another discrepancy in
the caffeine literature around the mounting evidence of
individual responses based on genotype [8]. Specifically,
CYP1A2 is the gene recently identified as a possible me-
diator of an individual’s response to caffeine ingestion. It
encodes for cytochrome P450 1A2; an enzyme respon-
sible for 95% of all caffeine metabolism [9], predomin-
antly to paraxanthine (~ 79%), but also theobromine (~
11%) and theophylline (~ 4%). Those with a homogenous
A allele of the CYP1A2 gene tend to produce more cyto-
chrome P450, metabolize caffeine more quickly [10] and
experience a significantly greater ergogenic effect of caf-
feine compared to those with a C allele in some [11, 12]
but not all [13, 14] studies. However, if elevated plasma
caffeine is the primary driver of observed ergogenic ef-
fects then, paradoxically, ‘slow’ metabolisers should see
the greatest benefit. Thus, perhaps paraxanthine, a
pharmacologically more potent adenosine-receptor an-
tagonist that would be elevated sooner in ‘fast’ metaboli-
sers, is responsible for the ergogenic properties of
caffeine [15]. Indeed, in rats, paraxanthine, but not caf-
feine, also significantly increases extracellular dopamine
levels in the dorsolateral striatum, increasing locomotor
activation [16].
The aim of the present study was to investigate the ef-
fect on performance of timing of the ingestion of com-
mercially available drink containing a low (200 mg, ~ 2.8
mg kg bm− 1) dose of caffeine, 1600mg of β-alanine,
1000 mg of quercetin and 4.5 g sucrose [Beachbody Per-
formance Energize, Beachbody LLC, USA] before a 15-
min cycling TT in trained cyclists. It was hypothesised
that the ingestion of caffeine 70 vs. 35 and 0min prior
to the TT would improve performance via a reduction
in perceived exertion and correspond with greater circu-
lating caffeine and paraxanthine.
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Methods
Participants
Fourteen (12 male, 2 female) well-trained cyclists (all
had competitive time trial and/or triathlon experience,
and 9 of whom were competitive road or criterium
racers) were recruited (age 28 ± 2 years, bm 71 ± 2 kg,
height 175 ± 3 cm, V̇O2max 64.5 ± 1.4 (range 58.2 to
71.2) mL kg bm− 1 min− 1, Wmax 334 ± 10W). Via the
use of questionnaires to assess both daily caffeine in-
take, and pre-race caffeine strategies, it was ascer-
tained that eleven of the participants were habitual
caffeine users (≥ 50 mg day− 1), and 7 regularly used
caffeine as part of their pre- and/or during race rou-
tines. Both female participants were taking a com-
bined oral contraceptive pill for the duration of the
study to negate for any potential effects of menstrual
cycle stage on caffeine metabolism. Following an ex-
planation of the experimental protocol and its risks,
all individuals provided written, informed consent.
The study was approved by the University of Exeter
Sport and Health Sciences Ethics Committee (161,
026/A/10).
Study design
Participants were randomly assigned a trial order in a
double-blinded four-treatment crossover design, with
each trial separated by a period of ≥ 7 days. On their first
visit, participants performed an incremental cycling test
to determine maximal oxygen consumption (V̇O2max).
The second visit was a familiarization of the experimen-
tal trials, and visits 3–6 were experimental trials. Each of
the 4 experimental trials consisted of participants resting
for 35 min before performing 30min of steady-state (SS)
cycling at a workload aimed at eliciting 80% V̇O2max,
preceding a standardized 5-min rest period and a 15-
min time trial (TT) (Fig. 1). During the initial 35-min
rest period, participants completed visual analogue scales
and consumed a test drink. In order to maximize the
validity of findings, we employed an exercise protocol
similar to one previously employed (45-min pre-load at
70% Wmax followed by a TT), where the coefficient of
variation of the TT was reported as 3.5% [17]. On three
of the experimental trials, participants consumed a 473
mL drink either 35 min before SS exercise (PRE), at the
onset of SS (ONS), or immediately before the time trial
(DUR) phases, with a 473 mL placebo drink consumed
at the other two time points (i.e. three drinks per visit).
The other visit (PLA) consisted of consuming the pla-
cebo drink at all three time points. The commercially
available drink contained 200 mg of caffeine (~ 2.8 mg
kg bm− 1, range 2.4 to 3.4 mg kg bm− 1), 1600 mg of β-
alanine, 1000mg of quercetin and 4.5 g sucrose (Beach-
body Performance Energize, Beachbody LLC, USA). The
placebo was taste-, colour- and calorie-matched and also
contained 4.5 g sucrose.
Pre-experimental tests
Two weeks prior to the first experimental visit, partici-
pants completed a continuous incremental V̇O2max test
on an electronically braked cycle ergometer (Lode
Excalibur Sport, Lode, The Netherlands). Following a
self-selected warm-up, participants began cycling at a
power output of 150W. The resistance was then in-
creased by 40W every 3 min until volitional exhaustion.
Fig. 1 Overview of the experimental protocol. CAFF, a commercially available beverage containing 200mg of caffeine; PLA, placebo drink; HR,
heart rate; RPE, rating of perceived exertion; VAS, visual analogue scales for alertness and paraesthesia. Treatments were randomly assigned in a
crossover design
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Throughout the duration of the test, participants wore a
face mask attached to a metabolic cart (Jaeger Oxycon
Pro, CareFusion, Switzerland). V̇O2max was determined
as the highest 15-s average. Following a 10-min rest
period, participants were familiarized with the 15-min
TT protocol.
One week prior to their first experimental visit, partic-
ipants were familiarized with the experimental protocol
(Fig. 1). During the SS cycle, V̇O2 was measured repeat-
edly to help adjust and establish the workload required
to elicit 80% V̇O2max. Participants could drink water ad
libitum throughout the SS cycle. Bike position was noted
at the end of the familiarization trial and then replicated
for all experimental visits.
Experimental trials
Participants reported to the laboratory following an
overnight fast at the same time for each trial, before
providing a pre-trial mid-stream urine sample for
analysis of urine osmolality (Pocket Osmocheck,
Vitech Scientific, UK), and body mass was measured
(SECA 780, Germany) (Pre-Ex). A cannula was then
inserted into an antecubital vein which was kept pa-
tent by a 0.9% sodium chloride drip (~ 1.8 mLmin− 1).
A sample of blood was drawn, immediately followed
by the consumption of the first experimental drink.
Participants then rested for 35 min before heart rate
(Polar, Finland); alertness and paraesthesia were re-
corded. Alertness and paraesthesia were measured by
participants marking a single line on separate, 20 cm,
visual analogue scales. A second experimental drink
was then consumed before the commencement of
cycling at 80% V̇O2max for 30 min and an immediate
recording of rating of perceived exertion (RPE). Fur-
ther measures of heart rate, RPE, alertness and par-
aesthesia were recorded at 10-min intervals
throughout the SS cycle. Blood samples were taken
immediately prior to the second experimental drink
and at subsequent 15-min intervals during the SS
cycle. A final blood sample was taken at the end of
the TT. For two 5-min periods (SS1 and SS2), expired
gases were recorded using a metabolic cart to determine
substrate oxidation rates. After cycling for 30min, partici-
pants had a 5-min rest period, before consuming their
third experimental drink, and immediately commencing a
15-min TT. The aim of the TT was to perform as much
work as possible. Heart rate and RPE were recorded at 5-
min intervals during the TT. Measures of alertness and
paraesthesia and a final blood sample were taken at the
end of the TT. After the TT, body mass was recorded, be-
fore another urine sample was provided. There were no
differences in laboratory temperature (18.4 ± 2.1 °C) or
humidity (48 ± 7%) between trials, and participants were
fan-cooled whilst cycling.
Dietary and exercise standardisation
In the 24 h preceding the familiarization trial, participants
were instructed to either rest or train lightly and eat a
high-carbohydrate diet. Meals and training sessions were
selected individually by the participants, dependent on
their preferred pre-race routine, but were approved by the
researchers. Participants were instructed to follow the
same diet and exercise practices before each trial, and
these were confirmed with the use of training and nutri-
tion diaries. Participants were asked to disclose the use of
any performance-enhancing supplements or drugs. Only
participants who were not using any ergogenic supple-
ments were included in the study. Furthermore, to
standardize pre-trial plasma caffeine concentrations, par-
ticipants were instructed to avoid caffeinated products for
18 h before the experimental trials.
Blood sampling and analysis
One mL of whole blood was immediately analysed for
glucose and lactate (YSI 2300 Stat Plus, USA). The
remaining blood was placed into a lithium heparin tube
containing 50 μL of EGTA glutathione, which was subse-
quently centrifuged for 10 min (4000×g, 4 °C). Samples
were frozen immediately at − 20 °C, before being trans-
ferred to a − 80 °C freezer. Plasma caffeine, paraxanthine,
theobromine and theophylline concentrations were
quantified via high-performance liquid chromatography
[18]. The ratio of paraxanthine to caffeine (PX:CA) at
the end of the PRE trial, i.e. when the concentration of
both metabolites was at a steady state, was calculated as
an index of CYP1A2 activity.
Genotyping
Saliva samples were collected on a separate lab visit at
the end of all physiological tests using the Oragene ON-
600kit (DNA Genotek, Ottawa, Ontario, Canada) for
DNA isolation using manufacturers recommended tech-
niques. A StepOnePlus Real-Time PCR System (Thermo
Fisher Scientific, USA) was used for the genotyping of
the rs762551 SNP in the CYP1A2 gene.
Calculations
Maximum work capacity (Wmax) was calculated using the
following equation: Wmax (W) =W′ + (40 · t/180) (where
W′ is the highest workload completed, and t (s) is the time
attained in the final, incomplete, stage at exhaustion dur-
ing the incremental exercise test). Substrate oxidation
rates were calculated using stoichiometric eqs [19].
Statistical analysis
TT performance was analysed using a repeated-
measures one-way ANOVA. Data passed the Shapiro-
Wilk test of normality. All other data (blood and plasma
metabolites, substrate oxidation, alertness, paraesthesia,
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heart rate, RPE, urine osmolality and body mass) were
analysed by repeated-measures two-way ANOVAs. The
two-way ANOVAs performed on blood lactate and glu-
cose, and plasma metabolites were run separately for SS
and TT periods. Specific differences were identified
using Tukey’s multiple comparisons post hoc tests. Ef-
fect sizes were determined by Cohen’s d. Statistical ana-
lyses were performed using GraphPad Prism 7
(GraphPad Software, Inc., USA). All data are presented




Following analysis of plasma caffeine concentrations, 1
female subject was excluded from all analyses due to
very high (> 7 μmol L− 1) baseline concentrations. Data
for plasma and blood metabolites are presented for n =
12 following blood-sampling problems in one trial. Of
the 13 participants, 7 were homozygous for the A allele
(AA), none were homozygous for the C allele (CC) and
6 were heterozygous (AC). Participants arrived at the la-
boratory with a similar body mass (71.0 ± 1.1 kg) and
urine osmolality (586 ± 37mOsmo kg− 1) for each trial.
Participants were infused intravenously with 164 ± 5mL
of 0.9% sodium chloride during each trial. Following the
trial, body mass remained unchanged (71.4 ± 1.1 kg), but
urine osmolality decreased (432 ± 26mOsmo kg− 1) (P <
0.0001). Two out of 13 participants identified the PLA
trial. In line with what would be expected from a suc-
cessfully blinded randomized trial, timing of drink ad-
ministration was correctly identified in 12 of the 39
trials (PRE = 5, ONS = 5, DUR = 2). Of the non-correctly
identified trials, 20 were unidentifiable, and 18 were in-
correctly guessed.
Time trial performance
There was a significant main effect for the timing of
drink ingestion on 15-min TT performance (P = 0.0082).
The average work done was 5% higher in PRE (3.53 ±
0.14 kJ kg bm− 1) than PLA (3.36 ± 0.13 kJ kg bm− 1, P =
0.025, d = 0.35) (Fig. 2a, b). There was no significant dif-
ference between PLA and ONS (3.44 ± 0.14 kJ kg bm− 1,
P = 0.3619, d = 0.17) or DUR (3.39 ± 0.14 kJ kg bm− 1, P =
0.925, d = 0.06), and no significant differences between
ONS, DUR or PLA. The average power output for each
of the trials were PLA 3.73 ± .015W kg bm− 1, DUR
3.76 ± .015W kg bm− 1, ONS 3.82 ± 0.16W kg bm− 1 and
Fig. 2 a Mean work done per kilogramme of body mass during a 15-min cycling time trial in the PLA, DUR, ONS and PRE trials. Data are mean
for all participants ± SEM. b Individuals participants’ work done per kilogramme of body mass during a 15-min cycling time trial in the PLA, DUR,
ONS and PRE trials. *P < 0.01, significantly different from PLA. Mean work done per kilogramme of body mass during a 15-min cycling time trial in
the PLA, DUR, ONS and PRE trials for c AA and d AC genotypes
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PRE 3.92 ± 0.16Wkg bm− 1. There were no differences in
performance improvement versus PLA between genotypes
in PRE (Fig. 2c, d) (AA 4.7 ± 1.5%, AC 5.4 ± 1.5%, P= 0.771),
ONS (AA 2.9 ± 1.9%, AC 1.7 ± 2.3%, P= 0.678) or DUR (AA
− 0.26 ± 2.2%, AC 2.4 ± 1.1%, P= 0.323).
30-min steady-state cycle
The average power output during the SS cycle was
243 ± 8W, which corresponded to 83 ± 1% V̇O2max.
There was no change in relative VO2max from SS1 to
SS2. There was no difference between conditions in cal-
culated carbohydrate or lipid oxidation (Fig. 3). There
was, however, an effect of time, as rates of carbohydrate
oxidation dropped from 58.6 ± 1.6 kJ min− 1 to 53.5 ± 1.7
kJ min− 1 (P < 0.0001), and lipid oxidation increased from
18.3 ± 1.4 to 23.2 ± 1.4 kJ min− 1 during SS1 and SS2, re-
spectively (P < 0.0001).
Blood and plasma metabolites
There were no differences in plasma caffeine concentra-
tions between conditions at baseline (Fig. 4a). Plasma
caffeine concentrations increased in all experimental
conditions following ingestion of the drink (P < 0.0001),
and there was a significant interaction effect, with peak
values observed at different time points (P < 0.0001).
Plasma paraxanthine concentrations were the same for
all conditions at baseline but increased over the duration
of the trial (P < 0.0001, Fig. 4b). There was also a main
effect for condition (P = 0.0343), with paraxanthine con-
centrations higher in PRE than all other conditions from
− 35 onwards and in ONS than DUR and PLA from − 20
onwards. There were no differences between conditions
in plasma theobromine concentrations (P = 0.7498,
Fig. 4c) or plasma theophylline concentrations (P =
0.4467, Fig. 4d). There was no difference between geno-
types in PX:CA at the end of TT in PRE, i.e. when the
concentration of both metabolites was at a steady state
(AA 0.27, AC 0.32, P = 0.17, d = 0.95). There was no cor-
relation between PX:CA and performance improvement
in PRE vs. PLA (r2 = 0.001, P = 0.9112).
There were no differences between conditions at
baseline, or at the start of the SS cycle, in blood glu-
cose concentrations, however, there was a significant
effect for condition (P = 0.0353), with glucose levels in
DUR significantly lower than ONS at the end of the
SS cycle (Fig. 4e). Blood glucose levels dipped
significantly mid-way through the SS cycle (P =
0.0037), before recovering to pre-exercise levels by
the end of SS.
Blood lactate concentrations rose throughout the SS
cycle (P < 0.0001) (Fig. 4f). Concentrations were signifi-
cantly higher in ONS compared to DUR and PLA but
not PRE (P = 0.033). During the TT, there was no signifi-
cant main effect for time or condition.
Rating of perceived exertion
During the SS cycle, there was a significant main ef-
fect for condition (P = 0.011), with max RPE in PRE
(13.5 ± 0.9) significantly lower than PLA and DUR
(14 ± 1 and 14.1 ± 0.9, respectively) (Fig. 5a). There
was no significant difference between PRE and ONS
(13.7 ± 0.9). RPE increased in all trials during the TT
(P < 0.0001), but there was no difference between
conditions.
Fig. 3 Calculated carbohydrate (CHO) and lipid (Lipid) oxidation during 30 min of SS cycling at 83 ± 1% VO2max in the PLA, DUR, ONS and PRE
trials. Expired gases were measured for two periods of 5 min (SS1 and SS2)
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Heart rate
Heart rate increased significantly during the SS cycle, to
a peak of 167 ± 1 beats min− 1 by the end (P < 0.0001),
but there were no differences between conditions
(Fig. 5b). Whilst heart rate also increased significantly
during the TT for all conditions (P < 0.0001), there were
significant differences between conditions (P = 0.002) in
line with the amount of work performed, with the peak
heart rate in PRE (179 ± 4 beats min− 1) exceeding those
in ONS (177 ± 4 beats min− 1), DUR (172 ± 5 beats min−
1) and PLA (172 ± 4 beats min− 1).
Alertness and Paraesthesia
There were no differences between conditions for either
alertness or paraesthesia throughout the trial (Fig. 6).
However, alertness decreased for all conditions through-
out the SS cycle (P < 0.0001).
Discussion
The present study assessed the optimal timing of inges-
tion of a low (200 mg, 2.8 ± 0.1 mg kg bm− 1) dose caf-
feine supplement, on perception of effort, plasma
caffeine metabolites and exercise performance. Cycling
Fig. 4 Plasma caffeine (a), paraxanthine (b), theobromine (c), theophylline (d), glucose (e) and lactate (f) during the PLA, DUR, ONS and PRE trials.
Data are mean for all participants ± SEM. Main effect for time: *, significant difference from − 70; #, significant difference from − 35; †, significant
difference from − 20. Main effect for condition: (a) PRE significantly different to ONS, PRE and PLA; (b) ONS significantly different to DUR and PLA;
(c) DUR significantly different to PLA and (d) DUR significantly different to DUR and PLA
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performance was improved by 5% following the inges-
tion of the supplement during the PRE condition (i.e.
around 30 min prior to beginning an exercise protocol
consisting of SS cycling at 80% V̇O2max, rest and an all-
out time trial). Despite an apparent time response, the
ingestion of the supplement at the onset (ONS) of, and
during (DUR), the exercise protocol had no effect on
performance. The lack of effect here was surprising
given that the ingestion of the supplement in ONS also
reduced perceived exertion during the SS exercise com-
pared with placebo. Intriguingly, whilst plasma caffeine
concentration was elevated prior to and during the TT
with all supplement timing strategies, paraxanthine was
only elevated prior to the TT when the supplement was
ingested in the PRE condition, the only strategy to
observe an ergogenic effect. It is important to note that
the supplement also contained quercetin and β-alanine,
and it is possible that they may have also contributed to
the ergogenic effect by a synergistic or additive mechan-
ism. However, there was no effect on performance when
quercetin and β-alanine were ingested at other time
points in the present study; previous findings suggest
that acute supplementation of β-alanine has no effect on
endurance performance, even in instances where athletes
are aware of the ingestion of a supplement [20], and a
recent meta-analysis concludes that chronic supplemen-
tation of quercetin has only ‘between trivial and small’
effects on performance [21]. Thus, the acute effect on
performance in the current study was likely driven by
caffeine as opposed to the other ingredients.
Fig. 5 a RPE and b heart rate during 30min of SS cycling at 80% VO2max and a 15-min time trial in the PLA, DUR, ONS and PRE conditions. Data
are mean for all participants ± SEM. Main effect for time: *, significant difference from − 35; #, significant difference from 0. Main effect for
condition: (a) significant difference between PRE and ONS, (b) significant difference between PRE and DUR, (c) significant difference between PRE
and PLA, (d) significant difference between ONS and DUR, (e) significant difference between ONS and PLA and (f) significant difference between
DUR and PLA
Fig. 6 Alertness (a) and paraesthesia (b) during the PLA, DUR, ONS and PRE trials. Data are mean for all participants ± SEM. *, significant
difference from − 25; #, significant difference from − 35
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The literature suggests there is no single optimal dose
of caffeine to improve performance. Whilst there seems
to be little doubt that high doses (> 6 mg kg bm− 1) of
caffeine do not provide any greater ergogenic effect
compared with lower doses (1.5 to 3 mg kg bm− 1), with
concomitant detrimental side effects also reported [7,
22], researchers have concluded that ~ 3mg kg bm− 1 is
the crucial optimal dose required to improve perform-
ance [1]. Indeed, supplementing with 1.5, 2 or 3 mg kg
bm− 1 caffeine around 60min before exercise improved
cycling TT performance similarly [23, 24]. However, nei-
ther a 1.5 nor 3 mg kg bm− 1 dose of caffeine 180 min
prior to a 7 kJ kg bm− 1 TT improved performance [25].
It would appear, therefore, that despite plasma caffeine
concentrations remaining elevated for several hours after
ingestion, there is an optimal time for ingesting low
doses (1.5 to 3 mg kg bm− 1) of caffeine before a TT, sug-
gesting elevated plasma caffeine concentrations per se
may not be the only causative mechanism. Thus, in line
with the findings that the ingestion of 2.9 mg kg bm− 1
caffeine around 55min prior to the last 15 min of a cyc-
ling TT improved performance by over 7% [23], and the
ingestion of either 2 or 3 mg kg bm− 1 caffeine 80min be-
fore a 15min cycling TT improved performance by 3
and 4%, respectively [24], we demonstrate that ingesting
a supplement containing 200 mg (2.8 mg kg bm− 1) caf-
feine 70min before a 15 min cycling TT improved per-
formance by 5%. Low-dose caffeine ingestion both 35
min and, in contrast to the typical advice, 5 min before
the final 15 min of a TT has also been shown to improve
performance but only by ~ 2% [26, 27]; however, these
findings were not replicated in the present study. Con-
sidering a low dose of caffeine 35 and 0min before a 15
min cycling TT failed to improve performance in the
present study, we can be more prescriptive and suggest
that an optimal time to ingest caffeine in order to en-
hance performance is around 60min before the end (i.e.
last 15 min) of exercise, where perceived effort is likely
to be extremely hard.
It has been proposed that inter-individual differences
in genotype may alter the efficacy of caffeine supplemen-
tation [25]. Indeed, recent work has shown striking dif-
ferences in the ergogenic efficacy of supplementing with
caffeine around 65 min before the last 15 min of a TT,
depending upon the genotype of the CYP1A2 gene [12].
It was demonstrated that 2 or 4 mg kg bm− 1 caffeine im-
proved 10-km cycling TT performance by 5 and 7%, re-
spectively, in those with the AA genotype, had no effect
on those with the AC genotype and reduced perform-
ance by 14% in those with the CC genotype. Conversely,
in the present study, whilst no participants had the CC
genotype, there was no difference in CYP1A2 enzyme
activity between those with the AA and AC genotypes,
as shown by similar PX:CA ratios in PRE, and
consequently, both groups found caffeine to be equally
efficacious at improving exercise performance. Differ-
ences between findings could be due to the contrasting
cycling abilities of participants recruited across studies,
with previous research employing relatively untrained in-
dividuals (V̇O2max 47.7 mL kgmin
− 1) [12] compared to
the present study (V̇O2max 64.5 mL kgmin
− 1). It is
known that regular exercise increases CYP1A2 expres-
sion [28], and it seems that the ‘slow metabolizing’ AC-
carrying athletes may be able to overcome any genetic
disadvantage with training to increase CYP1A2 activity
sufficiently. Whilst the results of the present study
should be viewed with caution due to the relatively small
sample size, our findings are in line with previous stud-
ies that have found that, in large samples sizes, there is
no effect for any CYP1A2 single-nucleotide polymorph-
ism or haplotype on caffeine metabolism, other than in
smokers with the AA genotype [29, 30]. Alternatively,
the additional ingredients of the supplement (β-alanine
and quercetin) may have affected caffeine metabolism.
Following the ingestion of each supplement, plasma
caffeine concentrations increased in all conditions, al-
though a plateau was only attained in PRE around 50
min after caffeine ingestion. This is in contrast with pre-
vious studies, which show that following the ingestion of
~ 200mg of caffeine, circulating caffeine concentrations
peaked at between 75- and 120-min post-
supplementation [26, 31]. Again, this could be due to
the training status of the participants or perhaps the
additional ingredients in the supplement affecting caf-
feine absorption. Nevertheless, this ensured that a peak
in plasma caffeine concentration was achieved in PRE
before the 15-min TT where performance was improved.
However, in ONS, plasma caffeine concentrations were
also elevated pre-TT, where no effect on performance
was observed. This would suggest that either the dur-
ation for which plasma caffeine was elevated was insuffi-
cient to cross the blood brain barrier and act on
adenosine receptors to affect performance, or that an in-
crease in the primary metabolite of caffeine, para-
xanthine, must also be attained. Indeed, at the start of
the TT plasma paraxanthine concentrations were ele-
vated in PRE but not ONS. Paraxanthine is a pharmaco-
logically more potent adenosine-receptor antagonist
than caffeine [15] and is thought to have additional ef-
fects on locomotor activity by increasing dopamine
levels in the dorsolateral striatum [16]. This suggests
that the principal mechanism for the observed perform-
ance improvements is a reduction in perceived exertion
mediated by increased paraxanthine and/or a combin-
ation of paraxanthine and caffeine, particularly as there
were no differences in peripheral responses during exer-
cise. It has been previously observed that when low-dose
caffeine is ingested 195 min prior to the final 15 min of a
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TT, it has no ergogenic effect [24]. As paraxanthine has
a half-life of 3.1 h [32], this may also suggest that a
threshold plasma paraxanthine concentration exists for
any performance effect. Clearly, our understanding of
the mechanisms of action of caffeine and paraxanthine
on exercise performance requires further investigation.
A recent meta-analysis has suggested that the ergogeni-
city of caffeine is related only to the duration of the
sport; however, we believe the findings of our current
study should complement, rather than juxtapose such
conclusions [33]. The present study investigated the ef-
fect of timing of caffeine supplementation on a 15-min
TT and found an effect of timing on its efficacy, and we
recommend that if people are performing for longer du-
rations, they may need to alter these recommendations
and ingest caffeine during exercise. We suggest that fu-
ture studies looking at the ergogenicity of caffeine
should quantify not only plasma caffeine, but plasma
paraxanthine, as standard practice.
Limitations
Although we cannot conclusively state that the add-
itional ingredient within the drink (β-alanine and quer-
cetin) had no effect on performance, previous research
and meta-analyses suggest that this is the case [20, 21].
A wide range of caffeinated supplements (e.g. gums,
drinks, capsules) are now available to athletes. However,
as the most likely method of caffeine ingestion during
cycling will be by a gel or drink, we chose to administer
caffeine via a commercially available drink. Additionally,
we chose to administer a standard, absolute dose of caf-
feine, rather than one relative to body mass. The
methods of caffeine delivery were chosen to mimic the
manner in which supplementation is typically provided,
to maximize the ecological validity of the outcomes;
however, practitioners should be prudent when applying
the findings of this study to other forms of caffeine ad-
ministration. Whilst there may be concerns over both
caffeine withdrawal and habituation, we are confident
that these will have been influential in the present study,
with previous research confirming that neither effect caf-
feine effectiveness [34, 35]. Unfortunately, the rating of
perceived exertion was the only perceptual measure used
in the present study to assess the potential central effects
of caffeine.
Conclusions
In summary, a supplement containing a low (200 mg,
2.8 mg kg bm− 1) dose of caffeine ingested 70min prior
to a 15-min cycling TT reduced perceived exertion dur-
ing cycling at 80% V̇O2max and improved performance in
trained cyclists by 5%. Whether these effects are due to
increases in circulating caffeine per se, the caffeine me-
tabolite paraxanthine or the combination of ingredients
requires further investigation. The same supplement
ingested 35 or 0 min prior to a 15-min TT had no effect
on perceived exertion or TT performance. Taken to-
gether with the results from other similar studies in the
literature, we suggest that cyclists should ingest supple-
ments containing low doses of caffeine (e.g. 200 mg)
around 60min prior to the onset of expected hard exer-
cise (i.e. 60 min before the last 15 min of exercise) in
order to reduce the perception of effort and maximize
the improvement in performance. This is an improve-
ment on the current broad recommendation of ingesting
caffeine-containing supplements 60 min before exercise
per se. Whilst we can only make conclusions around the
timing of caffeine ingestion in cyclists, a recent review of
meta-analyses found caffeine improved exercise in a
broad range of exercise modalities, with the magnitude
of effect generally greater for aerobic exercise compared
to anaerobic exercise [36]. Moreover, we recommend
that practitioners do not use genotyping as a tool to dis-
courage athletes from supplementing with caffeine,
partly because genotype did not affect performance in
this and other studies, but also because it is difficult to
distinguish normal day-to-day variation from individual
responses to a supplement [37]. It appears that the tim-
ing of caffeine is a much more important variable than
an individual’s genotype when considering its efficacy,
particularly in young, healthy individuals, such as ath-
letes. Whilst it is hard to mimic the reactive and dy-
namic nature of road cycling in a laboratory
environment, we believe the use of a validated time trial
test, together with the high standard of cyclists in the
present study, should give practitioners confidence in
applying these outcomes to highly trained endurance
athletes.
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